A novel, actionable pathway promoting metastasis of triple negative breast cancer

三阴性乳腺癌（TNBC）特别具有侵袭性，缺乏靶向治疗，限制了化疗的治疗。一种名为PEAK1的蛋白质驱动TNBC，但仍然“坚不可摧”。最近，我们发现了一种称为CAMK 2D的酶，它作用于PEAK 1的下游并介导其作用。在这项资助中，我们将描述CAMK 2D的机制，并确定阻断其作用的药物的作用。这可能导致TNBC的新的靶向和个性化治疗。

Triple negative breast cancer (TNBC) is particularly aggressive and lacks targeted therapies, limiting treatment to chemotherapy. A protein termed PEAK1 drives TNBC but has remained 'undruggable'. Recently, we identified an enzyme, termed CAMK2D, that acts downstream of PEAK1 and mediates its effects. In this grant we will characterize the mechanism of CAMK2D and determine the effect of a drug that blocks its action. This may lead to a new targeted and personalized treatment for TNBC.